ADvance-II Study Updates

ADvance-II is a multi-center clinical research trial investigating the efficacy of deep brain stimulation (DBS) for patients with mild Alzheimer’s disease. The study is sponsored by Functional Neuromodulation. DBS involves a brain implant which is being studied as a possible way to improve function in patients with Alzheimer’s disease. While the use of DBS for Alzheimer’s disease is new, DBS is FDA-approved as an effective treatment for other neurodegenerative diseases, such as Parkinson’s. The device is implanted just under the skin on the chest, and small leads are placed in the memory center of the brain to deliver electrical impulses to activate part of the brain that is affected by Alzheimer’s disease. We are looking to determine if this device will improve long-term function in patients with mild Alzheimer’s who are at least 65 years of age.

We are currently enrolling patients for this study. More information about this study can be found at the study sponsor’s webpage:

Eligibility Criteria:

  • At least 65 years old
  • Have a diagnosis of mild Alzheimer’s
  • Have a reliable caregiver to attend all study visits and report on daily activities and functions
  • Are currently taking, or have tried and failed, an FDA approved medication for Alzheimer’s disease, for example: Aricept (donepezil), Reminyl (galantamine), or Exelon (rivastigmine)


If you or someone in your care might be eligible for this study, or you would like more information, please contact us at 401-444-4362, or send us an email at

Updated 12/08/2020